3.2. Changes in Clinical Profiles
After 24 weeks of treatment, body weight, BMI, and waist circumference increased significantly by the glimepiride–metformin combination therapy but these did not alter by the gemigliptin-metformin combination therapy, resulting in no significant difference between the groups (Both groups showed a significant decrease in HbA1c levels; however, there was a slightly greater non-significant decrease in the gemigliptin–metformin group than in the glimepiride–metformin group (−2.1% vs. −1.7%; The gemigliptin–metformin combination treatment decreased the proinsulin/insulin ratio significantly, whereas the glimepiride–metformin combination treatment did not, resulting in a significant difference between the groups (